Foghorn Therapeutics Inc. (FHTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Foghorn Therapeutics Inc. on August 6, 2026. The filing serves to announce the Company's financial results for the quarter ended June 30, 2026, and to provide an investor presentation dated August 2026.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1 and the investor presentation furnished as Exhibit 99.2, which are referenced but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main text. Investors must refer to the attached press release (Exhibit 99.1) for a comparison of the quarter ended June 30, 2026, against previous periods.
Guidance, Outlook, and Risks
The Company furnished an investor presentation (Exhibit 99.2) intended for use in meetings with investors, which likely contains outlook and management commentary. The filing explicitly states that the information in Items 2.02 and 7.01, including the exhibits, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended June 30, 2026, by reviewing Exhibit 99.1 (Press Release).
- Review Exhibit 99.2 (Investor Presentation) for management's outlook and strategic updates.
- Note that the financial data in this 8-K is not legally "filed" under Section 18 of the Exchange Act, limiting liability exposure for the Company regarding these specific disclosures.
- Confirm the Company's status as an emerging growth company, as indicated by the checkmark in the filing header.